Hypolipidemic and Hepatoprotective Effects of Myricitrin and Solid Lipid Nanoparticle-containing Myricitrin on the Male Mouse Model with Type 2 Diabetes Induced by Streptozotocin-Nicotinamide

Document Type : Original Article

Authors

1 Professor of Physiology, Department of Physiology, Faculty of Medicine, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Assistant Professor of Physiology, Department of Physiology, Faculty of Medicine, Cellular and Molecular Research Center, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Associate Professor of Medical Histology, Department of Anatomical Sciences, Faculty of Medicine, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Professor of Pharmaceutics, Department of Pharmaceutics, Faculty of Pharmacy, Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

5 Professor of Physiology, Department of Physiology, Faculty of Medicine, Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

10.22062/jkmu.2021.91562

Abstract

Background: Type 2 diabetes mellitus (T2DM) has several complications such as hyperlipidemia and hepatotoxicity. Myricitrin has an antidiabetic action along with low bioavailability. So, the aim of the present study was to investigate hypolipidemic and hepatoprotective effects of myricitrin and solid lipid nanoparticle (SLN) containing myricitrin on the T2DM mouse model induced by Streptozotocin-nicotinamide (STZ-NA).
Methods: In this experimental study, 90 Naval Medical Research Institute (NMRI) adult male mice were divided into 9 groups (n=10 per group): control, vehicle, diabetic, diabetic + myricitrin, or SLN containing myricitrin 1, 3, and 10 mg/kg groups. The cold homogenization method was used to prepare SLN containing myricitrin. The diabetic model was induced by one injection of STZ-NA (65-120 mg/kg) with a 15-min interval. Animals' treatment was done for 4 weeks. At the end of the experiment, plasma samples were taken for experimental assessments.
Results: Plasma level of triglyceride (TG), low-density lipoprotein (LDL-C), very-low-density lipoprotein (VLDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) increased and high-density lipoprotein cholesterol (HDL-C) decreased in diabetic mice compared to the control group (p <0.05). Administration of myricitrin or SLN containing myricitrin decreased plasma levels of TG, LDL-C, VLDL, AST, and ALT and increased HDL-C in the treated diabetic groups compared to the untreated groups (p <0.05).
Conclusion: According to the results, myricitrin and SLN containing myricitrin showed hypolipidemic and hepatoprotective effects in T2DM mice. Also, SLN containing myricitrin was more potent than myricitrin especially in a low dose of administration.

Keywords


 Mahboobi S, Rahimi F, Jafarnejad S. Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials. Adv Pharm Bull 2018; 8(4):565-74.
Blaslov K, Naranđa FS, Kruljac I, Renar IP. Treatment approach to type 2 diabetes: Past, present and future. World J Diabetes 2018; 9(12):209-19.
Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015; 58(5):886-99.
Fernández-Gaxiola AC, Valdés-Ramos R, Fulda KG, López AL, Martínez-Carrillo BE, Franks SF, et al. Liver biomarkers and lipid profiles in Mexican and Mexican-American 10- to 14-year-old adolescents at risk for type 2 diabetes. J Diabetes Res 2017; 2017:4262536.
Akhlaghi M, Foshati S. Bioavailability and metabolism of flavonoids: a review. International Journal of Nutrition Sciences 2017; 2(4):180-4.
Yan LJ, Yang HT, Duan HY, Wu JT, Qian P, Fan XW, et al. Myricitrin inhibits vascular adhesion molecule expression in TNF‑α‑stimulated vascular smooth muscle cells. Mol Med Rep 2017; 16(5):6354-9.
Zhang B, Shen Q, Chen Y, Pan R, Kuang S, Liu G, et al. Myricitrin alleviates oxidative stress-induced inflammation and apoptosis and protects mice against diabetic cardiomyopathy. Sci Rep 2017; 7:44239.
White PA, Cercato LM, Batista VS, Camargo EA, De Lucca W Jr, Oliveira AS, et al. Aqueous extract of Chrysobalanus icaco leaves, in lower doses, prevent fat gain in obese high-fat fed mice. J Ethnopharmacol 2016; 179:92-100.
Ramteke KH, Joshi SA, Dhole SN. Solid lipid nanoparticle: a review. IOSR Journal of Pharmacy 2012; 2(6):34-44.
Szkudelski T. Streptozotocin–nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood) 2012; 237(5):481-90.
Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotinamide-induced rat model of type 2 diabetes. Acta Physiol Hung 2014; 101(4):408-20.
Ahangarpour A, Oroojan AA, Khorsandi L, Kouchak M, Badavi M. Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse. Oxid Med Cell Longev 2018; 2018:7496936.
Ahangarpour A, Oroojan AA, Khorsandi L, Arzani G, Afshari G. Effects of betulinic acid on the male reproductive system of a streptozotocin-nicotinamide-induced diabetic mouse model. World J Mens Health 2016; 34(3):209-16.
Meotti FC, Posser T, Missau FC, Pizzolatti MG, Leal RB, Santos AR. Involvement of p38MAPK on the antinociceptive action of myricitrin in mice. Biochem Pharmacol 2007; 74(6):924-31.
Schwanke RC, Marcon R, Meotti FC, Bento AF, Dutra RC, Pizzollatti MG, et al. Oral administration of the flavonoid myricitrin prevents dextran sulfate sodium‐induced experimental colitis in mice through modulation of PI 3 K/A kt signaling pathway. Mol Nutr Food Res 2013; 57(11):1938-49.
Ahangarpour A, Alboghobeish S, Rezaei M, Khodayar MJ, Oroojan AA, Zainvand M. Evaluation of diabetogenic mechanism of high fat diet in combination with arsenic exposure in male mice. Iran J Pharm Res 2018; 17(1):164-83.
Daniel MJ. Lipid management in patients with type 2 diabetes. Am Health Drug Benefits 2011; 4(5):312-22.
Sugden M, Holness M. Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology 2011; 6(4):401-11.
Testa R, Bonfigli AR, Genovese S, De Nigris V, Ceriello A. The possible role of flavonoids in the prevention of diabetic complications. Nutrients 2016; 8(5):310.
Kawser Hossain M, Abdal Dayem A, Han J, Yin Y, Kim K, Kumar Saha S, et al. Molecular mechanisms of the anti-obesity and anti-diabetic properties of flavonoids. Int J Mol Sci 2016; 17(4):569.
Gao J, Chen S, Qiu Z, Fang L, Zhang L, Guo C, et al. Myricitrin ameliorates ethanol-induced steatosis in mouse AML12 liver cells by activating AMPK, and reducing oxidative stress and expression of inflammatory cytokines. Mol Med Rep 2018; 17(5):7381-7.
Ahn HR, Shin MH, Nam HS, Park KS, Lee YH, Jeong SK, et al. The association between liver enzymes and risk of type 2 diabetes: the Namwon study. Diabetology & Metabolic Syndrome 2014; 6(1):14.
Kanter M. Protective effect of quercetin on liver damage induced by biliary obstruction in rats. J Mol Histol 2010; 41(6):395-402.
Johari H, Nozari M, Moghtari M, Zamani Z, Yazdani M. The effect of Myrtus communis extract on liver enzymes and blood biochemical factors in diabetic adult male rats. Zahedan Journal of Research in Medical Sciences (Tabib-E-Shargh) 2014; 16(10):12-7.
Domitrović R, Rashed K, Cvijanović O, Vladimir-Knežević S, Škoda M, Višnić A. Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chem Biol Interact 2015; 230:21-9.
Ruiz-Cruz S, Chaparro-Hernández S, Hernández-Ruiz KL, Cira-Chávez LA, Estrada-Alvarado MI, Gassos Ortega LE, et al. Flavonoids: important biocompounds in food. In: Justino GC. Flavonoids - From Biosynthesis to Human Health. London: IntechOpen; 2017:353-70.
Eghbaliferiz S, Iranshahi M. Prooxidant activity of polyphenols, flavonoids, anthocyanins and carotenoids: updated review of mechanisms and catalyzing metals. Phytother Res 2016; 30(9):1379-91.